Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Completed Phase 3 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00322101Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaTreatment